Spinal cord injury therapeutics market to grow 6.3% annually to 2017 says report
The report 'Acute Spinal Cord Injury (ASCI) Therapeutics: Pipeline Assessment and Market Forecasts to 2019' estimates the acute spinal cord injury (ASCI) therapeutics market to grow 6.3% annually to hit $68.76m in 2017. This growth is mainly attributed to the increasing incidence of SCIs and a larger treatment seeking population. The 65 page report reveals that the current competition in the ASCI therapeutics market is weak. The arket lacks a therapy specifically approved by the FDA